FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Carcinogenesis"
DOI: 10.1002/mc.22884
Abstract: Although genetic amplification and overexpression of the fibroblast growth factor 19 (FGF19) gene are found in human breast cancer, mechanisms that contribute to such functional alterations remain elusive. We report here that high expression of… read more here.
Keywords: breast; fgf19; breast cancer; fgfr4 ... See more keywords
Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2021.113794
Abstract: Aberrant activation of the fibroblast growth factor 19-fibroblast growth factor receptor 4 (FGF19-FGFR4) signaling pathway has been proved to promote hepatocellular carcinoma (HCC) proliferation. It is assumed that the first FGFR4 inhibitor BLU9931 did not… read more here.
Keywords: design synthesis; biological evaluation; evaluation quinazoline; quinazoline derivatives ... See more keywords
Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c00096
Abstract: Aberrant FGF19/FGFR4 signaling has been shown to be an oncogenic driver of growth and survival in human hepatocellular carcinoma (HCC) with several pan-FGFR inhibitors and FGFR4-selective inhibitors currently being evaluated in the clinic. However, FGFR4… read more here.
Keywords: fgfr4; inhibitors wild; type gatekeeper; gatekeeper ... See more keywords
Discovery of Novel 7-Azaindole Derivatives as Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the Treatment of Hepatocellular Carcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c00255
Abstract: Fibroblast growth factor receptor 4 (FGFR4) has been identified as a potential target for the treatment of hepatocellular carcinoma (HCC) with aberrant FGFR4 signaling because of its important role in HCC progression and development. Several… read more here.
Keywords: fgfr4; treatment hepatocellular; factor receptor; growth factor ... See more keywords
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-84117-9
Abstract: FGF19/FGFR4 autocrine signaling is one of the main targets for multi-kinase inhibitors (MKIs). However, the molecular mechanisms underlying FGF19/FGFR4 signaling in the antitumor effects to MKIs in hepatocellular carcinoma (HCC) remain unclear. In this study,… read more here.
Keywords: fgf19 fgfr4; hcc; inhibition; multi kinase ... See more keywords
Induction of FGFR4 by H. pylori via STAT3 with a feedforward activation loop involving SRC signaling in gastric cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Gastroenterology"
DOI: 10.1053/j.gastro.2022.05.016
Abstract: BACKGROUND & AIMS Helicobacter pylori (H. pylori) infection is the main risk factor for gastric cancer. The role of Fibroblast Growth Factor Receptors in H. pylori-mediated gastric tumorigenesis remains largely unknown. This study investigated the… read more here.
Keywords: activation loop; fgfr4; feedforward activation; gastric cancer ... See more keywords
FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-22-0059
Abstract: Abstract Rhabdomyosarcoma (RMS) is the most common soft tissue cancer in children. Treatment outcomes, particularly for relapsed/refractory or metastatic disease, have not improved in decades. The current lack of novel therapies and low tumor mutational… read more here.
Keywords: anti myeloid; fgfr4; fgfr4 targeted; chimeric antigen ... See more keywords
Abstract 693: Antibody-based targeting of the cell surface receptor tyrosine kinase FGFR4 in rhabdomyosarcoma and other cancers
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-693
Abstract: Fibroblast Growth Factor Receptor 4 (FGFR4) is a receptor tyrosine kinase that is highly expressed in rhabdomyosarcoma (RMS), an aggressive soft tissue sarcoma originating from skeletal muscle in children and adolescent young adults. FGFR4 is… read more here.
Keywords: receptor tyrosine; fgfr4; rhabdomyosarcoma; receptor ... See more keywords
Abstract 2592: Helicobacter pylori-induced FGFR4 mediates nuclear accumulation of NRF2 in gastric tumorigenesis
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2592
Abstract: Background: Fibroblast growth factor receptor 4 (FGFR4) is a member of the transmembrane tyrosine kinase receptor family and has been linked to a variety of malignancies. NRF2 (Nuclear factor-erythroid 2-related factor) is a cytoprotective factor… read more here.
Keywords: nuclear accumulation; fgfr4; accumulation nrf2; accumulation ... See more keywords
Abstract LB328: Discovery & characterization of a next-generation FGFR4 inhibitor overcoming resistant mutations
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-lb328
Abstract: Introduction: Aberrant activation of FGF19-FGFR4 signaling pathway plays an essential role in the tumorigenesis of Hepatocellular carcinoma (HCC) and FGFR4 inhibitors have shown preliminary efficacy in recent clinical trials for patients with FGF19 overexpression. However,… read more here.
Keywords: fgfr4; generation fgfr4; generation; next generation ... See more keywords
Abstract A08: Development of FGFR4-specific chimeric antibody receptor (CAR) T cell and bispecific T cell engager (BiTE) for rhabdomyosarcoma (RMS) immunotherapy
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.pedca19-a08
Abstract: Background: Despite decades of multimodule therapies, RMS remains incurable once it has metastasized; thus, new therapeutic strategies are warranted. FGFR4 is a developmentally regulated cell surface receptor tyrosine kinase, overexpressed in virtually all, mutationally activated… read more here.
Keywords: antibody; fgfr4; receptor; rms immunotherapy ... See more keywords